Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G CLELAND

Showing results (51-60 of 663) with videos related to

Pageof 67
Sort By:
Postgraduate Medical Journal|May 1, 1980
Hepatoma and obstructive jaundiceP G Cleland, A Adjukiewicz
European Heart Journal|May 1, 1997
Is medical treatment for angina the most cost-effective option?J G Cleland, A Walker
The American Journal of Cardiology|March 25, 1999
Has the survival of the heart failure population changed? Lessons from trialsJ G Cleland, A Clark
European Heart Journal|July 1, 1996
SPAF-III resultsP Cowburn, J G Cleland
Current Opinion in Cardiology|May 1, 1996
Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical researchJ G Cleland, K Morgan
The Journal of Experimental Medicine|April 1, 1992
Depletion of alpha/beta T cells by a monoclonal antibody against the alpha/beta T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in ratsS Yoshino, L G Cleland
British Heart Journal|September 1, 1994
How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death?J G Cleland, S Puri
European Journal of Heart Failure|August 11, 2000
Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial TeamP Mylona, J G Cleland
Journal of Cardiovascular Risk|August 27, 1999
Influence of aetiology on the effects of treatment in heart failureJ G Cleland, K Swedberg
Lancet (London, England)|June 27, 1998
Interpretation of Thrombosis Prevention TrialJ G Cleland, I Ford
Pageof 67

Showing results (51-60 of 663) with videos related to

Sort By:
Pageof 67
Postgraduate Medical Journal|May 1, 1980
Hepatoma and obstructive jaundiceP G Cleland, A Adjukiewicz
European Heart Journal|May 1, 1997
Is medical treatment for angina the most cost-effective option?J G Cleland, A Walker
The American Journal of Cardiology|March 25, 1999
Has the survival of the heart failure population changed? Lessons from trialsJ G Cleland, A Clark
European Heart Journal|July 1, 1996
SPAF-III resultsP Cowburn, J G Cleland
Current Opinion in Cardiology|May 1, 1996
Inhibition of the renin-angiotensin-aldosterone system in heart failure: new insights from basic clinical researchJ G Cleland, K Morgan
The Journal of Experimental Medicine|April 1, 1992
Depletion of alpha/beta T cells by a monoclonal antibody against the alpha/beta T cell receptor suppresses established adjuvant arthritis, but not established collagen-induced arthritis in ratsS Yoshino, L G Cleland
British Heart Journal|September 1, 1994
How do ACE inhibitors reduce mortality in patients with left ventricular dysfunction with and without heart failure: remodelling, resetting, or sudden death?J G Cleland, S Puri
European Journal of Heart Failure|August 11, 2000
Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial TeamP Mylona, J G Cleland
Journal of Cardiovascular Risk|August 27, 1999
Influence of aetiology on the effects of treatment in heart failureJ G Cleland, K Swedberg
Lancet (London, England)|June 27, 1998
Interpretation of Thrombosis Prevention TrialJ G Cleland, I Ford
Pageof 67